Navigation Links
Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer
Date:9/22/2009

BETHESDA, Md., Sept. 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the appointment of Jan Fagerberg, M.D., Ph.D., as Senior Vice President and Chief Medical Officer effective November 1, 2009.

Dr. Fagerberg is a board-certified clinical oncologist and has more than 20 years of experience in clinical research and development of oncology drugs. His experience includes several years at F. Hoffmann-La Roche in positions of increasing responsibility both in the US and in Switzerland, ultimately serving as the Therapeutic Area Expert Oncology in Global Drug Development of Hoffmann-La Roche in Basel, Switzerland. During his tenure at Roche, he was responsible for the global clinical development of Xeloda, and for the clinical development programs of Avastin outside the US. He was also advising Roche's clinical development teams globally on the development of all compounds for the treatment of gastrointestinal cancers. Dr. Fagerberg has extensive US and European regulatory experience, and was successful in obtaining 11 FDA and EMEA approvals for Xeloda and Avastin. Dr. Fagerberg joins Micromet from TopoTarget where he was Medical Director responsible for the pivotal clinical development program for belinostat for the treatment of peripheral T-cell lymphoma.

"We are very pleased to have Jan Fagerberg join us as our new Chief Medical Officer," said Christian Itin, Micromet's Chief Executive Officer. "Jan's extensive clinical and regulatory experience will be a tremendous asset as we are preparing pivotal stage clinical trials for blinatumomab."

"I am excited about the opportunity to advance the development of bli
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors
2. Micromet to Host Conference Call and Webcast to Discuss MT110 Data Presented at ECCO/ESMO on September 22, 2009
3. Micromet to Present at the UBS Global Life Sciences Conference on September 22, 2009
4. Micromet to Present at the 16th Annual NewsMakers in the Biotech Industry Conference on September 16, 2009
5. Micromet Closes $80.5 Million Public Offering of Common Stock
6. Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab
7. Micromet Announces Pricing of Public Offering of Common Stock
8. Micromet Announces Public Offering of Common Stock
9. Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009
10. Micromet Added to Russell 3000 Index
11. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Md. , Sept. 2, 2014  Synthetic ... novel anti-infective biologic and drug candidates targeting specific ... today positive results from its final preclinical toxicology ... Administration (FDA) guidance, this bridging study was required ... candidate designed to prevent the devastating effects of ...
(Date:9/2/2014)... -- Culot brings life science and software ... BioData, producer of Labguru, the web-based research ... appointment of Louis Culot as the company,s ... and Business Development at BioDiscovery Inc., developer of genomics ... Previously, Culot worked for 17 years with CambridgeSoft ...
(Date:9/1/2014)... 01, 2014 The Collaborative R&D ... report provides comprehensive understanding and unprecedented access to ... by the worlds leading life science companies. , ... of how and why companies enter collaborative R&D ... partner’s negotiated deals terms provides critical insight into ...
(Date:8/31/2014)... This is a professional and in-depth ... Hardener industry in Global and China. The ... including definitions, applications and industry chain structure. Global ... provided with a focus on history, developments, trends ... between the international and Chinese situation is also ...
Breaking Biology Technology:Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5Louis Culot Appointed as BioData's CEO 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3
... Leading ... procedures through the roll-out of a global Summer seminar and exhibition programme that ... test methods within the pharmaceutical industry. , ... Belfast (Vocus) May 5, 2010 -- Package integrity is key ...
... Inc. (Pink Sheets: DYAI) ("Dyadic"), a leading-edge early-stage biotechnology company, is pleased to ... , , ... , , ... as Executive Director of Strategic Alliances . Ms. Whitehead brings to Dyadic ...
... MELBOURNE , May 4, 2010 Ansell today announced the ... of the Royal Australasian College of Surgeons in, Perth, Australia . , ... It is the first ... protection to,surgical staff against viruses and bacteria, in the event of a breach ...
Cached Biology Technology:Pharmaceutical Leak Testing Practices challenged by SEPHA 2Pharmaceutical Leak Testing Practices challenged by SEPHA 3Dyadic International Strengthens Management Team 2Dyadic International Strengthens Management Team 3Dyadic International Strengthens Management Team 4Dyadic International Strengthens Management Team 5Ansell Launches Worlds's First Antimicrobial Surgical Glove 2
(Date:8/31/2014)... they are not busy attacking us, germs go after ... always spell disaster for the infected microbes: Sometimes viruses ... to, say, expand its diet or better attack its ... of an immune system would robotically destroy anything it ... Rockefeller University have now revealed that one variety of ...
(Date:8/31/2014)... the past several decades, malaria diagnosis has changed very little. ... smears the blood across a glass slide, stains it with ... Plasmodium parasite, which causes the disease. This approach gives an ... an important measure of disease severity but is ... A research team from the Singapore-MIT Alliance for Research and ...
(Date:8/29/2014)... (Aug. 29, 2014) Scientists at the Barshop Institute ... of Medicine at the UT Health Science Center at ... the tissues of the longest-lived rodent, the naked mole ... the cells of naked mole rats protects and alters ... damaged and obsolete proteins. , The factor also protects ...
Breaking Biology News(10 mins):Discovery reveals how bacteria distinguish harmful vs. helpful viruses 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 3A new way to diagnose malaria 2A new way to diagnose malaria 3Factor in naked mole rat's cells enhances protein integrity 2
... A new neuroimaging study conducted by researchers from the ... de Montral at the International laboratory for Brain Music ... amusic individuals have more grey matter in specific regions ... the right interior frontal gyrus and the right auditory ...
... Approximately one in every 500 to 650 baby boys is ... genetic code that until a few years ago was thought ... no longer the case. A recent conference hosted by NewYork-Presbyterian ... raising awareness of the condition and the recent availability of ...
... chew up rattlesnake skin and smear it on their ... a new study by researchers at UC Davis. ... UC Davis, observed ground squirrels (Spermophilus beecheyi) and rock ... picking up pieces of shed snakeskin, chewing it and ...
Cached Biology News:Jingle bells not merry for tone-deaf individuals 2Jingle bells not merry for tone-deaf individuals 3Physician-scientists seek solutions to reproductive problems related to chromosomal variations 2Physician-scientists seek solutions to reproductive problems related to chromosomal variations 3
Mouse Anti-Human Killer Cell Immunoglobulin-like Receptor, Two Domains, Long Cytoplasmic Tail, 2 (KIR2DL2 (KIR2DL3 Monoclonal Antibody Family: Immunoglobulin Sub-Family: not assigned-Immunogl...
pH-dependent fluorescence; Maximum intensity observed in basic solutions....
Mouse anti human pro-Relaxin-2...
Mouse Anti-Human Kallikrein 2 (Hk2)...
Biology Products: